{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["30(10)"],"submitter":["Goetz MP"],"funding":["n/a"],"pubmed_abstract":["<h4>Purpose</h4>To identify potential predictors of response and resistance mechanisms in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) treated with the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor abemaciclib ± endocrine therapy (ET), baseline and acquired genomic alterations in circulating tumor DNA (ctDNA) were analyzed and associated with clinical outcomes.<h4>Experimental design</h4>MONARCH 3: postmenopausal women with HR+, HER2- ABC and no prior systemic therapy in the advanced setting were randomly assigned to abemaciclib or placebo plus nonsteroidal aromatase inhibitor (NSAI). nextMONARCH: women with HR+, HER2- metastatic breast cancer that progressed on/after prior ET and chemotherapy were randomly assigned to abemaciclib a"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pagination":["2233-2244"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11094424"],"repository":["biostudies-literature"],"pubmed_title":["Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer."],"pmcid":["PMC11094424"],"pubmed_authors":["Graham H","Campone M","Jerusalem G","Toi M","Hamilton EP","Hurvitz SA","Wang H","Llombart-Cussac A","Jansen VM","Litchfield LM","Goetz MP","Cortes J","Martin M","Johnston S","Kaufman PA"],"additional_accession":[]},"is_claimable":false,"name":"Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.","description":"<h4>Purpose</h4>To identify potential predictors of response and resistance mechanisms in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) treated with the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor abemaciclib ± endocrine therapy (ET), baseline and acquired genomic alterations in circulating tumor DNA (ctDNA) were analyzed and associated with clinical outcomes.<h4>Experimental design</h4>MONARCH 3: postmenopausal women with HR+, HER2- ABC and no prior systemic therapy in the advanced setting were randomly assigned to abemaciclib or placebo plus nonsteroidal aromatase inhibitor (NSAI). nextMONARCH: women with HR+, HER2- metastatic breast cancer that progressed on/after prior ET and chemotherapy were randomly assigned to abemaciclib a","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-06-02T01:42:05.76Z","creation":"2026-04-13T03:12:01.704Z"},"accession":"S-EPMC11094424","cross_references":{"pubmed":["37889120"],"doi":["10.1158/1078-0432.CCR-22-3573"]}}